• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    11/14/24 1:42:23 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care
    Get the next $STIM alert in real time by email
    SC 13G/A 1 ccllc_STIM_13g11112024.htm SCHEDULE 13G/A

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    SCHEDULE 13G/A

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

    (Amendment No.2)


    NEURONETICS, INC.

    (Name of Issuer)

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    64131A105

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☑   Rule 13d-1(b)

    ☐   Rule 13d-1(c)

    ☐   Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

         The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    CUSIP No.64131A105 Page 2 of 7 Pages
    1

    NAMES OF REPORTING PERSONS

    J. Carlo Cannell

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    USA

    NUMBER OF SHARES

    BENEFICIALLY OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,314,266

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,314,266

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,314,266

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐

    (see instructions)

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

    4.34%

    12

    TYPE OF REPORTING PERSON

    IN

     
    CUSIP No.64131A105 Page 3 of 7 Pages
    1

    NAMES OF REPORTING PERSONS

    Cannell Capital LLC

    I.R.S. Identification Nos. of Above Persons (Entities Only)

    94-3366999

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Wyoming, USA

    NUMBER OF SHARES

    BENEFICIALLY OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,314,266

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,314,266

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,314,266

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐

    (see instructions)

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

    4.34%

    12

    TYPE OF REPORTING PERSON

    IA

     
    CUSIP No.64131A105 Page 4 of 7 Pages
    Item 1.

    a)

    Name of Issuer

    Neuronetics, Inc.

    b)

    Address of issuer's principal executive offices:

    3222 Phoenixville Pike

    Malvern, PA 19355

    Item 2.

    a)

    Name of person filing:

    Cannell Capital LLC

    b)

    Address or principal business office or, if none, residence:

    245 Meriwether Circle

    Alta, WY 83414

    c)

    Citizenship:

    Wyoming, USA

    d)

    Title of class of securities:

    Common Stock

    e)

    CUSIP No.:

    64131A105

    Item 3.
    If this statement is filed pursuant to §240.13d-1(b) or §240.13d-2(b) or (c), check whether the person filing is a:

    (a)

    ☐

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b)

    ☐

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)

    ☐

    Insurance company as defined in section 3(a)(19) of the Act(15 U.S.C. 78c).

    (d)

    ☐

    An Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

    (e)

    ☑

    An investment adviser in accordance with Section §240.13d-1(b)(1)(ii)(E).

    (f)

    ☐

    An Employee benefit plan or endowment fund in accordance with Section §240.13d-1(b)(1)(ii)(F).

    (g)

    ☐

    A Parent holding company or control person in accordance with Section §240.13d-1(b)(1)(ii)(G).

    (h)

    ☐

    A Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

    (i)

    ☐

    A Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).

    (j)

    ☐

    A non-U.S. institution in accordance with Section §240.13d-1(b)(1)(ii)(J).

    (k)

    ☐

    Group, in accordance with Section §240.13d-1(b)(1)(ii)(J).

     
    CUSIP No.64131A105 Page 5 of 7 Pages
    Item 4. Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a)

    Amount beneficially owned: 1,314,266.

    (b)

    Percent of class: 4.34%.

    (c)

    Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote 0.
    (ii) Shared power to vote or to direct the vote 1,314,266.
    (iii) Sole power to dispose or to direct the disposition of 0.
    (iv) Shared power to dispose or to direct the disposition of 1,314,266. Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

    Item 5. Ownership of 5 Percent or Less of a Class.
    Not Applicable.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.
    Not Applicable.

    Item 9. Notice of Dissolution of Group.
    Not Applicable.

    Item 10. Certifications.
    Not Applicable.

     
    CUSIP No.64131A105 Page 6 of 7 Pages

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    11/14/2024                            

    Date       

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Cannell Capital LLC

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Title:  Managing Member

     
    CUSIP No.64131A105 Page 7 of 7 Pages

    Exhibit A

    Agreement Regarding the Joint Filing of Schedule 13G

    The undersigned hereby agree as follows:
    1) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf each of them;
    2) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Cannell Capital LLC

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Title:  Managing Member

    Get the next $STIM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STIM

    DatePrice TargetRatingAnalyst
    8/13/2024Outperform → Mkt Perform
    William Blair
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    10/13/2021Outperform → Mkt Perform
    William Blair
    10/13/2021Buy → Neutral
    BTIG
    More analyst ratings

    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to one new non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, a

      6/19/25 7:00:56 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial Program

      MALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, is proud to share two significant updates underscoring its ongoing commitment to clinical excellence and innovation in mental health care. This week, NeuroStar will attend the 13th Annual Clinical TMS Society (CTMSS) Meeting, taking place June 11–14 in San Diego, CA as a Silver Sponsor. NeuroStar will present two poster presentations derived from the TrakStar® data set, the largest real-world outcomes database in TMS. Data hi

      6/10/25 8:31:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

      MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strate

      6/2/25 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 27% to 140,890 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:18 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Conley Sheryl L was granted 30,000 shares, increasing direct ownership by 16% to 214,390 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:13 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Amin Avinash was granted 30,000 shares, increasing direct ownership by 240% to 42,500 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:15 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care